HighTide Therapeutics, Inc.

SEHK:2511 주식 보고서

시가총액: HK$622.9m

HighTide Therapeutics 과거 수익 실적

과거 기준 확인 0/6

HighTide Therapeutics has been growing earnings at an average annual rate of 9.8%, while the Biotechs industry saw earnings growing at 31.7% annually.

주요 정보

9.8%

수익 성장률

9.1%

EPS 성장률

Biotechs 산업 성장11.0%
매출 성장률n/a
자기자본 수익률-109.4%
순이익n/a
최근 수익 업데이트30 Jun 2024

최근 과거 실적 업데이트

Recent updates

We're A Little Worried About HighTide Therapeutics' (HKG:2511) Cash Burn Rate

Oct 05
We're A Little Worried About HighTide Therapeutics' (HKG:2511) Cash Burn Rate

Is HighTide Therapeutics (HKG:2511) In A Good Position To Invest In Growth?

Jun 21
Is HighTide Therapeutics (HKG:2511) In A Good Position To Invest In Growth?

수익 및 비용 분석

HighTide Therapeutics 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.


수익 및 매출 내역

SEHK:2511 수익, 비용 및 수입 (CNY Millions )
날짜수익수익G+A 비용R&D 비용
30 Jun 240-601131393
31 Mar 240-770134353
31 Dec 230-939137312
30 Sep 230-803102269
30 Jun 230-66667226
31 Mar 230-42855205
31 Dec 220-19043183

양질의 수익: 2511 is currently unprofitable.

이익 마진 증가: 2511 is currently unprofitable.


잉여현금흐름 대 수익 분석


과거 수익 성장 분석

수익추이: Insufficient data to determine if 2511's year-on-year earnings growth rate was positive over the past 5 years.

성장 가속화: Unable to compare 2511's earnings growth over the past year to its 5-year average as it is currently unprofitable

수익 대 산업: 2511 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.5%).


자기자본 수익률

높은 ROE: 2511 has a negative Return on Equity (-109.45%), as it is currently unprofitable.


자산 수익률


고용 자본 수익률


과거 성과가 우수한 기업 찾기